We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Controlled Esophageal Stent System Aids Precise Placement

By HospiMedica staff writers
Posted on 30 Jun 2008
A new minimally invasive esophageal stent system helps improve the quality of life of terminal patients with an advanced esophageal cancer, allowing them to eat normally instead of through a tube.

The Evolution controlled release esophageal stent system incorporates a retractable delivery system that facilitates direct monitoring of the placement progress throughout the procedure, allowing physicians more controlled placement of the stent. More...
Each squeeze of the stents trigger-based introducer deploys or recaptures a proportional length of the stent. The bi-directional button enables seamless switching from deployment to recapture mode and a "point-of-no-return” mark alerts the physician when recapture is no longer available; however, even after this point is reached, repositioning is still an option. The Evolution stent is designed with dual flanges that secure the stent, potentially reducing the risk of migration or stent movement after placement, thus eliminating the need for repeat procedures. The stent also possesses both an internal and external silicone coating, designed to resist tumor growth into the stent and enhance the patients' ability to swallow food normally. The Evolution controlled release esophageal stent system is a product of Cook Medical (Bloomington, IN, USA), and has been approved by the U.S. Food and Drug Administration (FDA); the system has also received the European Community CE marking.

"We are thrilled to introduce Evolution to the market as the first and only recapturable stent deployment system,” said Barry Slowey, vice president of global sales and marketing for Cook Medical's endoscopy division. "Since launching the first esophageal stent more than 20 years ago, Cook has continued to pioneer new innovations in this market with the goal of improving patient care. With a unique set of features, like the ability to recapture, reposition, and control the deployment of the stent, Evolution leapfrogs any other esophageal stent system on the market today.”

Esophageal cancer tumors usually lead to dysphagia (difficulty in swallowing), pain, and other symptoms, and are diagnosed via biopsy. Small and localized tumors are treated surgically; larger tumors tend not to be operable and hence cannot be cured; their growth, however, can still be delayed with chemotherapy, radiotherapy, or a combination of the two. In some cases chemo- and radiotherapy can render these larger tumors operable. Prognosis depends on the extent of the disease and other medical problems, but is fairly poor. Risk factors for esophageal cancer include alcohol consumption, lye indigestion, tobacco, gastroesophageal reflux disease (GERD) and obesity. Typically, an esophageal stent is used in the treatment of esophageal cancer patients whose condition has advanced beyond surgical treatment options.


Related Links:
Cook Medical

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Bipolar Coagulation Generator
Aesculap
Mobile X-Ray System
K4W
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The researchers grew pancreatic tissue (above) so it incorporated a mesh-like electronic network (red). Cells within the tissue produce insulin (green). (Photo courtesy of Penn Medicine)

‘Cyborg’ Transplants Could Replace Pancreatic Tissue Damaged by Diabetes

Type 1 diabetes destroys insulin-producing islet cells, forcing patients to rely on lifelong insulin therapy or scarce organ transplants. Although lab-grown pancreatic tissue offers a promising alternative,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.